Computer simulations showed that 30 μM Epigallocatechin-3-Gallate reduces and suppresses action potential abnormalities associated with Nav1.5 gain-of-function mutations.
Does Epigallocatechin-3-Gallate (E3G) reduce action potential abnormalities in computer simulations of cardiac sodium channelopathies with hyperexcitability phenotypes?
In silico simulations suggest that Epigallocatechin-3-Gallate (E3G) may have beneficial antiarrhythmic effects in cardiac sodium channelopathies with hyperexcitability phenotypes.
Ion channels are transmembrane proteins that allow the passage of ions according to the direction of their electrochemical gradients. Mutations in more than 30 genes encoding ion channels have been associated with an increasingly wide range of inherited cardiac arrhythmias. In this line, ion channels become one of the most important molecular targets for several classes of drugs, including antiarrhythmics. Nevertheless, antiarrhythmic drugs are usually accompanied by some serious side effects. Thus, developing new approaches could offer added values to prevent and treat the episodes of arrhythmia. In this sense, green tea catechins seem to be a promising alternative because of the significant effect of Epigallocatechin-3-Gallate (E3G) on the electrocardiographic wave forms of guinea pig hearts. Thus, the aim of this study was to evaluate the benefits-risks balance of E3G consumption in the setting of ion channel mutations linked with aberrant cardiac excitability phenotypes. Two gain-of-function mutations,Nav1.5-p.R222Q andNav1.5-p.I141V, which are linked with cardiac hyperexcitability phenotypes were studied. Computer simulations of action potentials (APs) show that 30 μ M E3G reduces and suppresses AP abnormalities characteristics of these phenotypes. These results suggest that E3G may have a beneficial effect in the setting of cardiac sodium channelopathies displaying a hyperexcitability phenotype.
Boukhabza et al. (Fri,) conducted a other in Cardiac sodium channelopathies. Epigallocatechin-3-Gallate (E3G) was evaluated on Action potential abnormalities. Computer simulations showed that 30 μM Epigallocatechin-3-Gallate reduces and suppresses action potential abnormalities associated with Nav1.5 gain-of-function mutations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: